{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-26-000050","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2026-08-05T20:09:28+00:00","discovered_at":"2026-08-05T20:10:13.884978+00:00","generated_at":"2026-08-05T20:10:57.654401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Akebia Q2 2026: Vafseo revenue $21.3M (+34% QoQ); net loss $8.9M","bullets":["Vafseo net product revenue $21.3M in Q2 2026, up 34% from Q1; over 10,500 patients on therapy.","Total revenue $49.1M, down 20% YoY due to Auryxia generic competition ($25.5M vs $47.2M).","Net loss of $8.9M vs net income of $0.2M in Q2 2025; includes $1.9M restructuring charge.","Cash $155.5M as of June 30; company expects to fund operations for at least two years.","Initiated Phase 2 basket trial of ebribafusp for rare kidney diseases; initial data expected 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-26-000050","json":"https://secwatch.observer/filing/0001517022-26-000050.json","markdown":"https://secwatch.observer/filing/0001517022-26-000050.md","text":"https://secwatch.observer/filing/0001517022-26-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/0001517022-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000050/akba-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:10:57.654401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}